[go: up one dir, main page]

WO2005000348A3 - Vaccines inducing nkt-cell and toll-like-receptor activation - Google Patents

Vaccines inducing nkt-cell and toll-like-receptor activation Download PDF

Info

Publication number
WO2005000348A3
WO2005000348A3 PCT/GB2004/002726 GB2004002726W WO2005000348A3 WO 2005000348 A3 WO2005000348 A3 WO 2005000348A3 GB 2004002726 W GB2004002726 W GB 2004002726W WO 2005000348 A3 WO2005000348 A3 WO 2005000348A3
Authority
WO
WIPO (PCT)
Prior art keywords
cell
toll
nkt
receptor activation
relates
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/GB2004/002726
Other languages
French (fr)
Other versions
WO2005000348A2 (en
Inventor
Vincenzo Cerundolo
Ian Hermans
Uzi Gileadi
Jonathan Silk
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Oxford University Innovation Ltd
Original Assignee
Oxford University Innovation Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oxford University Innovation Ltd filed Critical Oxford University Innovation Ltd
Publication of WO2005000348A2 publication Critical patent/WO2005000348A2/en
Publication of WO2005000348A3 publication Critical patent/WO2005000348A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/542—Mucosal route oral/gastrointestinal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55583—Polysaccharides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

The invention relates to materials and methods for improving vaccination strategies. Particularly, but not exclusively, the present invention relates to the use of an activator of NKT cells, in combination with an activator of Toll-like receptors, to enhance T-cell responses to soluble antigen. The invention also relates to the use of particular NKT cell activators, e.g. OCH, to enhance T-cell responses to soluble antigen. The materials and methods of the invention are particularly suitable for enhancing presentation of the soluble antigen via the MHC I molecules of dendritic cells and so stimulating cytotoxic T cell responses against the antigen.
PCT/GB2004/002726 2003-06-24 2004-06-24 Vaccines inducing nkt-cell and toll-like-receptor activation Ceased WO2005000348A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB0314682.6 2003-06-24
GBGB0314682.6A GB0314682D0 (en) 2003-06-24 2003-06-24 Materials and methods relating to the modulation of T cell response to soluble antigen

Publications (2)

Publication Number Publication Date
WO2005000348A2 WO2005000348A2 (en) 2005-01-06
WO2005000348A3 true WO2005000348A3 (en) 2005-03-24

Family

ID=27637222

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB2004/002726 Ceased WO2005000348A2 (en) 2003-06-24 2004-06-24 Vaccines inducing nkt-cell and toll-like-receptor activation

Country Status (2)

Country Link
GB (1) GB0314682D0 (en)
WO (1) WO2005000348A2 (en)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9809654B2 (en) 2002-09-27 2017-11-07 Vaccinex, Inc. Targeted CD1d molecules
US7645873B2 (en) 2003-03-20 2010-01-12 The Scripps Research Institute 6″-amino-6″-deoxygalactosylceramides
GB0419846D0 (en) 2004-09-07 2004-10-13 Chiron Srl Vaccine adjuvants for saccharides
BRPI0607299A2 (en) 2005-01-28 2009-08-25 Univ Brigham Young activation of bacterial glycolipid from cd1d restricted nkt cells
KR20080082893A (en) * 2006-01-13 2008-09-12 도꾸리쯔교세이호징 리가가쿠 겐큐소 Prevention and treatment and method of immune disease
GB0605247D0 (en) * 2006-03-15 2006-04-26 Chiron Srl Compositions and methods for immunisation
US8227581B2 (en) 2006-04-07 2012-07-24 The Scripps Research Institute Modified α-galactosyl ceramides for staining and stimulating natural killer T cells
WO2008005824A1 (en) 2006-06-30 2008-01-10 The Scripps Research Institute Adjuvants and methods of use
US9603922B2 (en) 2007-02-21 2017-03-28 Vaccinex, Inc. Modulation of NKT cell activity with antigen-loaded CD1d molecules
US8916164B2 (en) 2007-08-29 2014-12-23 Abivax Methods of enhancing adjuvaticity of vaccine compositions
US8697659B2 (en) 2007-10-12 2014-04-15 Luigi Panza Analogues of glycolipids useful as immunoadjuvants
EP2058011A1 (en) 2007-11-07 2009-05-13 Wittycell Nkt cell activating gycolipids covalently bound antigens and/or drug
PT2231145E (en) 2007-12-05 2014-12-23 Wittycell Use of glycosylceramides for enhancing the immune response to antigens
EP2341931A1 (en) 2008-10-08 2011-07-13 Wittycell Vaccine composition for use against influenza
KR101928684B1 (en) 2009-01-08 2018-12-12 앨버트 아인슈타인 컬리지 오브 메디신, 인크. Bacterial vaccines with cell wall-associated ceramide-like glycolipids and uses thereof
EP2865390B1 (en) * 2012-06-20 2019-08-21 The University of Tokyo Mucosal immunity-stimulating agent, and oral pharmaceutical composition for treating hpv infection
US9371352B2 (en) 2013-02-08 2016-06-21 Vaccinex, Inc. Modified glycolipids and methods of making and using the same
WO2014124245A1 (en) 2013-02-08 2014-08-14 Vaccinex, Inc. Modified glycolipids and methods of making and using the same
TW201442739A (en) * 2013-02-27 2014-11-16 Riken Allergic disease therapeutic drug
GB2514591A (en) * 2013-05-30 2014-12-03 Mologen Ag Predictive biomarker for cancer therapy
EP2952372A1 (en) 2014-06-04 2015-12-09 AGC Glass Europe Glazing including a liquid-crystal film
EP2955976A1 (en) 2014-06-12 2015-12-16 AGC Glass Europe Heating glass
AU2017294751B2 (en) * 2016-07-13 2023-10-05 Ohio State Innovation Foundation Platforms and methods for optimizing host antigen presentation and host antitumor and antipathogen immunity
WO2021045632A1 (en) * 2019-09-04 2021-03-11 Victoria Link Ltd Cancer vaccine
WO2021231541A1 (en) * 2020-05-14 2021-11-18 Nutcracker Therapeutics, Inc. Polynucleotides comprising an antigenic payload

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003009812A2 (en) * 2001-07-25 2003-02-06 New York University Use of glycosylceramides as adjuvants for vaccines against infections and cancer

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003009812A2 (en) * 2001-07-25 2003-02-06 New York University Use of glycosylceramides as adjuvants for vaccines against infections and cancer

Non-Patent Citations (9)

* Cited by examiner, † Cited by third party
Title
BENDELAC ALBERT ET AL: "Adjuvants of immunity: Harnessing innate immunity to promote adaptive immunity", JOURNAL OF EXPERIMENTAL MEDICINE, vol. 195, no. 5, 4 March 2002 (2002-03-04), pages F19 - F23, XP002303682, ISSN: 0022-1007 *
BUSCHARD K ET AL: "Sulphatide and its precursor, galactosylceramide, influence the production of cytokines in human mononuclear cells", DIABETOLOGIA, vol. 40, no. SUPPL. 1, 1997, & 16TH INTERNATIONAL DIABETES FEDERATION CONGRESS; HELSINKI, FINLAND; JULY 20-25, 1997, pages A89, XP009039007, ISSN: 0012-186X *
HAYAKAWA Y ET AL: "Differential regulation of Th1 and Th2 functions of NKT cells by CD28 and CD40 costimulatory pathways.", JOURNAL OF IMMUNOLOGY (BALTIMORE, MD. : 1950) 15 MAY 2001, vol. 166, no. 10, 15 May 2001 (2001-05-15), pages 6012 - 6018, XP002303681, ISSN: 0022-1767 *
KITAMURA HIDEMITSU ET AL: "The natural killer T (NKT) cell ligand alpha-galactosylceramide demonstrates its immunopotentiating effect by inducing interleukin (IL)-12 production by dendritic cells and IL-12 receptor expression on NKT cells", JOURNAL OF EXPERIMENTAL MEDICINE, vol. 189, no. 7, 5 April 1999 (1999-04-05), pages 1121 - 1127, XP002303680, ISSN: 0022-1007 *
KRUTZIK S R ET AL: "The role of Toll-like receptors in host defense against microbial infection", CURRENT OPINION IN IMMUNOLOGY, CURRENT BIOLOGY LTD, XX, vol. 13, no. 1, 1 February 2001 (2001-02-01), pages 104 - 108, XP004257769, ISSN: 0952-7915 *
LIM SAI-KIANG: "Freund adjuvant induces TLR2 but not TLR4 expression in the liver of mice.", INTERNATIONAL IMMUNOPHARMACOLOGY, vol. 3, no. 1, January 2003 (2003-01-01), pages 115 - 118, XP002303684, ISSN: 1567-5769 *
MIYAMOTO KATSUICHI ET AL: "A synthetic glycolipid prevents autoimmune encephalomyelitis by inducing TH2 bias of natural killer T cells", NATURE (LONDON), vol. 413, no. 6855, 4 October 2001 (2001-10-04), pages 531 - 534, XP002303730, ISSN: 0028-0836 *
YANAGISAWA KAZUHIKO ET AL: "Impaired proliferative response of Valpha24 NKT cells from cancer patients against alpha-galactosylceramide", JOURNAL OF IMMUNOLOGY, vol. 168, no. 12, 15 June 2002 (2002-06-15), pages 6494 - 6499, XP002303685, ISSN: 0022-1767 *
YOSHIMURA ATSUTOSHI ET AL: "Structural requirements of muramylpeptides for induction of Toll-like receptor 2-mediated NF-kappaB activation in CHO cells", JOURNAL OF ENDOTOXIN RESEARCH, vol. 6, no. 5, 2000, pages 407 - 410, XP002303683, ISSN: 0968-0519 *

Also Published As

Publication number Publication date
WO2005000348A2 (en) 2005-01-06
GB0314682D0 (en) 2003-07-30

Similar Documents

Publication Publication Date Title
WO2005000348A3 (en) Vaccines inducing nkt-cell and toll-like-receptor activation
Zom et al. Efficient induction of antitumor immunity by synthetic toll-like receptor ligand–peptide conjugates
HUE038833T2 (en) Generation of antigen specific T cells
WO2006050172A3 (en) Combination cancer immunotherapy with co-stimulatory molecules
Sprent Direct stimulation of naive T cells by antigen-presenting cell vesicles
MXPA05013973A (en) Methods to elicit, enhance and sustain immune responses against mhc class i-restricted epitopes, for prophylactic or therapeutic purposes.
WO2009133378A3 (en) Products and methods for stimulating an immune response
WO2007065957A3 (en) Methods for generating antigen-specific effector t cells
EP2441468A3 (en) Immunotherapy by using cell capable of co-expressing target antigen and cd1d and pulsed with cd1d ligand
MX2009008918A (en) Activation of human antigen-presenting cells through clec-6.
WO2006026389A3 (en) Ceramide derivatives as modulators of immunity and autoimmunity
WO2009117616A3 (en) Carbon nanotube compositions and methods of use thereof
WO1999042564A3 (en) Apoptotic cell-mediated antigen presentation to dendritic cells
WO2008073635A3 (en) Automatable artificial immune system (ais)
WO2007108835A3 (en) Automatable artificial immune system (ais)
IL218447A0 (en) Co-culture lymphoid tissue equivalent (lte) for an artificial immune system (ais)
WO2008108794A3 (en) Controlling dendritic cell maturation state in the lymphoid tissue equivalent of an artificial immune system
WO1999000137A3 (en) Induction of an activated myeloid dendritic cell phenotype
NZ584606A (en) An ex vivo, fast and efficient process to obtain activated antigen-presenting cells that are useful for therapies against cancer and immune system-related diseases
WO2002074345A3 (en) Immune modulation by transduced hematopoietic stem cells expressing antigens and antigen-presenting cell regulatory molecules
GB0503936D0 (en) Method
WO2009101475A3 (en) Use of glycosylceramides for enhancing the immune response to antigens
SG158154A1 (en) Methods to elicit, enhance and sustain immune responses against mhc class i-restricted epitopes, for prophylactic or therapeutic purposes
WO2006012416A3 (en) Specific inhibition of autoimmunity and diseases associated with autoantigens
WO2009032256A3 (en) Apc activators in combination with a cytokine-secreting cell and methods of use thereof

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase